Valerio Therapeutics Société anonyme (EPA:ALVIO)

France · Delayed Price · Currency is EUR

0.146

-0.004 (-2.67%)

At close: Feb 27, 2026

181.85% (1Y)

Market Cap	71.37M
Revenue (ttm)	1.83M
Net Income (ttm)	-13.18M
Shares Out	488.85M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,382,887
Average Volume	311,713
Open	0.150
Previous Close	0.150
Day's Range	0.144 - 0.170
52-Week Range	0.042 - 0.310
Beta	1.62
RSI	47.47
Earnings Date	Mar 30, 2026

About EPA:ALVIO

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand. It also develops V-body platform, a bis... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1997

Employees 25

Stock Exchange Euronext Paris

Ticker Symbol ALVIO

Full Company Profile

Financial Performance

In 2024, EPA:ALVIO's revenue was 1.79 million, a decrease of -0.39% compared to the previous year's 1.80 million. Losses were -23.93 million, 17.6% more than in 2023.

Financial Statements

News

There is no news available yet.